A Drug-Drug Interaction Study To Investigate The Ginkgolides Meglumine Injection To Alter The Pharmacokinetics Of Midazolam

Inclusion criteria

• Ages 18-40.
• Male.
• Subjects have standard weight( generally not less than 50 kg), and body mass index (BMI) within 19-25.
• All physical examinations( including ECG, kidney function, liver function, blood routine, urine routines, etc) are normal.
• Subjects have no history of significant diseases, allergy or orthostatic hypotension.
• All subjects sign the informed consent after being informed all possible adverse drug reaction and .are able to complete all examination defined.

Exclusion criteria

• Subjects who cannot communicate with medical staff, and subjects with cerebral insufficiency or psychological problem.
• Partner of subjects have plan to pregnant.
• Subject have primary disease in vital organ.
• Subjects have a history of drug dependence or psychosis in last 2 years.
• Subjects with severe blood loss or blood donation more than 200 mL in the prior 3 months.
• Subjects who have participated in another clinical trial within the prior 3 months.
• Known or suspected to have a history of alcohol or drug abuse.
• Subjects who have abnormal clinical significance after checking preclinical laboratory data and physical examinations.
• Known allergy to pharmaceutical ingredient of Ginkgolides Meglumine Injection or allergy sufferers who are allergic to more than two kinds of food or drugs in the past.
• Subjects who have used any drugs in the prior 2 weeks.
• Subjects have unexplained infections.
• The subjects could not complete the study in the opinion of the Principal Investigator due to any reason.
• Subjects who test positive at screening for human immunodeficiency virus (HIV), hepatitis C virus (HCV) , hepatitis B surface antigen (HbsAg), etc.